Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups
- PMID: 22904263
- PMCID: PMC3567234
- DOI: 10.1136/annrheumdis-2012-201851
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups
Abstract
Objectives: The Xq28 region containing IRAK1 and MECP2 has been identified as a risk locus for systemic lupus erythematosus (SLE) in previous genetic association studies. However, due to the strong linkage disequilibrium between IRAK1 and MECP2, it remains unclear which gene is affected by the underlying causal variant(s) conferring risk of SLE.
Methods: We fine-mapped ≥136 SNPs in a ∼227 kb region on Xq28, containing IRAK1, MECP2 and seven adjacent genes (L1CAM, AVPR2, ARHGAP4, NAA10, RENBP, HCFC1 and TMEM187), for association with SLE in 15 783 case-control subjects derived from four different ancestral groups.
Results: Multiple SNPs showed strong association with SLE in European Americans, Asians and Hispanics at p<5×10(-8) with consistent association in subjects with African ancestry. Of these, six SNPs located in the TMEM187-IRAK1-MECP2 region captured the underlying causal variant(s) residing in a common risk haplotype shared by all four ancestral groups. Among them, rs1059702 best explained the Xq28 association signals in conditional testings and exhibited the strongest p value in transancestral meta-analysis (p(meta )= 1.3×10(-27), OR=1.43), and thus was considered to be the most likely causal variant. The risk allele of rs1059702 results in the amino acid substitution S196F in IRAK1 and had previously been shown to increase NF-κB activity in vitro. We also found that the homozygous risk genotype of rs1059702 was associated with lower mRNA levels of MECP2, but not IRAK1, in SLE patients (p=0.0012) and healthy controls (p=0.0064).
Conclusions: These data suggest contributions of both IRAK1 and MECP2 to SLE susceptibility.
Figures



References
-
- Kaiser R, Criswell LA. Genetics research in systemic lupus erythematosus for clinicians: methodology, progress, and controversies. Curr Opin Rheumatol. 2010 Mar;22(2):119–125. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21AI070304/AI/NIAID NIH HHS/United States
- P01AR49084/AR/NIAMS NIH HHS/United States
- R01AR43814/AR/NIAMS NIH HHS/United States
- P60AR049459/AR/NIAMS NIH HHS/United States
- UL1 TR000154/TR/NCATS NIH HHS/United States
- RC1AR058621/AR/NIAMS NIH HHS/United States
- UL1 RR024148/RR/NCRR NIH HHS/United States
- K24 AI078004/AI/NIAID NIH HHS/United States
- K08AI083790/AI/NIAID NIH HHS/United States
- P60 AR053308/AR/NIAMS NIH HHS/United States
- R01 AI063274/AI/NIAID NIH HHS/United States
- M01 RR000079/RR/NCRR NIH HHS/United States
- M01RR-00079/RR/NCRR NIH HHS/United States
- P20 RR020143/RR/NCRR NIH HHS/United States
- P30 GM103510/GM/NIGMS NIH HHS/United States
- U19AI082714/AI/NIAID NIH HHS/United States
- U19 AI082714/AI/NIAID NIH HHS/United States
- UL1RR025741/RR/NCRR NIH HHS/United States
- P20RR020143/RR/NCRR NIH HHS/United States
- P30 AR053483/AR/NIAMS NIH HHS/United States
- UL1 RR024999/RR/NCRR NIH HHS/United States
- R01AR043274/AR/NIAMS NIH HHS/United States
- P30AR055385/AR/NIAMS NIH HHS/United States
- P01AI083194/AI/NIAID NIH HHS/United States
- K08 AI083790/AI/NIAID NIH HHS/United States
- U01 AI090909/AI/NIAID NIH HHS/United States
- 5UL1RR025777/RR/NCRR NIH HHS/United States
- UL1 RR025741/RR/NCRR NIH HHS/United States
- AR042460/AR/NIAMS NIH HHS/United States
- N01 AR062277/AR/NIAMS NIH HHS/United States
- RC1 AR058621/AR/NIAMS NIH HHS/United States
- P60 AR048098/AR/NIAMS NIH HHS/United States
- P30 AR048311/AR/NIAMS NIH HHS/United States
- P30 CA046934/CA/NCI NIH HHS/United States
- P30048311/PHS HHS/United States
- R01 AR043814/AR/NIAMS NIH HHS/United States
- P60 AR049459/AR/NIAMS NIH HHS/United States
- R37 AI024717/AI/NIAID NIH HHS/United States
- R01 AR042460/AR/NIAMS NIH HHS/United States
- R01 AR057172/AR/NIAMS NIH HHS/United States
- R01AR051545-01A2/AR/NIAMS NIH HHS/United States
- R01AR33062/AR/NIAMS NIH HHS/United States
- R01 AR033062/AR/NIAMS NIH HHS/United States
- R01CA141700/CA/NCI NIH HHS/United States
- R01AI063274/AI/NIAID NIH HHS/United States
- UL1 RR025777/RR/NCRR NIH HHS/United States
- K24AR002138/AR/NIAMS NIH HHS/United States
- UL1 RR025014/RR/NCRR NIH HHS/United States
- UL1 RR029882/RR/NCRR NIH HHS/United States
- L30 AI071651/AI/NIAID NIH HHS/United States
- R3724717/PHS HHS/United States
- R01 CA141700/CA/NCI NIH HHS/United States
- P30GM103510/GM/NIGMS NIH HHS/United States
- P602AR30692/AR/NIAMS NIH HHS/United States
- K24 AR002138/AR/NIAMS NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- P60AR053308/AR/NIAMS NIH HHS/United States
- UL1RR024999/RR/NCRR NIH HHS/United States
- R21 AI070304/AI/NIAID NIH HHS/United States
- P01 AI083194/AI/NIAID NIH HHS/United States
- P01 AR052915/AR/NIAMS NIH HHS/United States
- R01 AR060861/AR/NIAMS NIH HHS/United States
- P60 AR030692/AR/NIAMS NIH HHS/United States
- 1U54RR23417-01/RR/NCRR NIH HHS/United States
- P01 AR049084/AR/NIAMS NIH HHS/United States
- R01 AR051545/AR/NIAMS NIH HHS/United States
- P30AR053483/AR/NIAMS NIH HHS/United States
- UL1RR029882/RR/NCRR NIH HHS/United States
- R01 AR043274/AR/NIAMS NIH HHS/United States
- P60 AR062755/AR/NIAMS NIH HHS/United States